Daphne Quimi - 08 Jun 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Director
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Issuer symbol
AMLX
Transactions as of
08 Jun 2023
Net transactions value
$0
Form type
4
Filing time
12 Jun 2023, 19:39:51 UTC
Previous filing
19 Jan 2023
Next filing
29 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (right to buy) Award $0 +16,985 $0.000000 16,985 08 Jun 2023 Common Stock 16,985 $26.25 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest in full upon the earlier of (i) June 8, 2024 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Remarks:

Exhibit List: Exhibit 24. This Power of Attorney was inadvertently omitted from the Form 3 filed on January 6, 2022.